Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12021344 | 1.00 | L3MBTL1 (0.41) | L3MBTL1MCL1KDM4EMEN1KMT2A | |
| SCHEMBL19696616 | 0.86 | USP30 (0.42) | MCL1USP30ABCB1PDE4B | |
| SCHEMBL1750041 | 0.84 | ELANE (0.39) | MCL1MEN1KMT2A | |
| SCHEMBL12529490 | 0.84 | ELANE (0.39) | MCL1MEN1KMT2A | |
| SCHEMBL12021345 | 0.84 | USP30 (0.44) | MCL1USP30ABCB1 | |
| SCHEMBL1751337 | 0.84 | USP30 (0.44) | MCL1USP30ABCB1 | |
| SCHEMBL12021130 | 0.83 | L3MBTL1 (0.41) | L3MBTL1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL4816625 | 0.81 | L3MBTL1 (0.39) | L3MBTL1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL12021327 | 0.81 | L3MBTL1 (0.39) | L3MBTL1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL12529508 | 0.81 | MEN1 (0.37) | MCL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840464-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20160289183-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-9394249-B2 | IAP binding compounds | TetraLogic Birinapant UK Ltd. (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150307448-A1 | IAP Binding Compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2015-10-29 | — | — | US | disclosed |
| US-8802716-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130289075-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20110294827-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-7968590-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | US | disclosed |
| US-7456209-B2 | IAP binding compounds | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060025347-A1 | IAP binding compounds | MEDIVIR AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289183-A1 | IAP Binding Compounds | BIRC5, API5, BIRC2 | L3MBTL1 434/4885MCL1 41/4885KDM4E 3837/4885 |
| US-20130289075-A1 | IAP BINDING COMPOUNDS | API5, BIRC5, BIRC2 | L3MBTL1 420/4885MCL1 42/4885KDM4E 3767/4885 |
| US-20150307448-A1 | IAP Binding Compounds | BIRC5, API5, BIRC2 | L3MBTL1 434/4885MCL1 41/4885KDM4E 3837/4885 |
| US-20110294827-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | L3MBTL1 389/4885MCL1 43/4885KDM4E 3718/4885 |
| US-20060025347-A1 | IAP binding compounds | BIRC5, BIRC2, API5 | L3MBTL1 389/4885MCL1 43/4885KDM4E 3718/4885 |
| US-20090048183-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC2, API5 | L3MBTL1 389/4885MCL1 43/4885KDM4E 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.